Microbiological preparation for preventing or treating diabetes and related symptoms

A technology of microbial preparations and related diseases, which is applied in the field of medicine to achieve the effect of reducing the amount of absorption

Inactive Publication Date: 2009-12-09
萧湘
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether phenylalanine ammonia lyase exists in the human body is still inconclusive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microbiological preparation for preventing or treating diabetes and related symptoms
  • Microbiological preparation for preventing or treating diabetes and related symptoms
  • Microbiological preparation for preventing or treating diabetes and related symptoms

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1 .Effects of InsBM and InsCA on hyperglycemia rats induced by high-fat diet-STZ

[0072] Objective: To study the effects of InsBM and InsCA on the diabetic rat model induced by high-fat diet combined with streptozotocin (STZ). Methods: After feeding Wistar rats with high-fat diet for 4 weeks, fasting for 12 hours, intraperitoneally injecting 1.2% streptozotocin 30 mg / kg, and injecting equal volume of citrate buffer to the blank group. One week later, the rats with successful modeling were randomly divided into model group, metformin group, InsCA group and InsBM group. The treatment group was intragastrically administered InsBM and InsCA, both 20ml / kg.bw, and metformin aqueous solution 500mg / kg.bw; the model group was intragastrically administered equal volume of distilled water, once a day. Blood glucose, plasma insulin, glycosylated hemoglobin and blood lipids were tested 2 weeks after administration, and the insulin sensitivity index was calculated. Resul...

Embodiment 2

[0086] Example 2. Effects of InsBM and InsCA on normal mice and alloxan-induced hyperglycemia mice

[0087] Objective: To study the effects of InsBM and InsCA on blood glucose and glucose tolerance in normal and diabetic mice. Methods: Male ICR mice, weighing 20-24 g. Normal ICR mice were administered orally, and fasting blood glucose and glucose tolerance were measured; alloxan-induced diabetic ICR mouse models were orally administered, and fasting blood glucose and glucose tolerance were measured. Results: InsBM and InsCA had no hypoglycemic effect on normal mice, but they could flatten the glucose tolerance curve; InsBM and InsCA lowered blood glucose in diabetic mice, significantly improved glucose tolerance and resisted the rise of blood glucose in diabetic mice.

[0088] blood sugar Forty normal mice were randomly divided into 4 groups, 10 in each group: the blank control group was gavaged with distilled water, and the positive control group, InsBM group and InsCA...

Embodiment 3

[0107] Example 3. Effects of InsBM and InsCA on Experimental Obese Rats

[0108] Objective: To study the effect of InsBM and InsCA on weight loss in nutritionally obese rats. Methods: Weaned Wistar male rats, weighing 48-72 g, with an average of (55.14±5.07) g, were randomly divided into two groups, one group was fed with normal diet, and the other group was fed with high-fat diet. After 9 weeks, a rat model of nutritional obesity was made. They were randomly divided into 4 groups, namely model group, metformin group, InsCA group and InsBM group. Metformin aqueous solution 500mg / kg.bw, InsBM, InsCA both 20ml / kg.bw were administered intragastrically, and the model group was intragastrically administered an equal volume of distilled water. Each group was administered once a day for 9 consecutive weeks. Body weight, food intake, and testicular fat weight were recorded. Results: After administration, the body weight of rats in InsBM group, InsCA group and metformin group inc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the medicine field, in particular to an application of a microbiological preparation for preventing or treating diabetes, in particular 2-type diabetes and related symptoms thereof. The related symptoms comprise adiposity, insulin resistance, hyperinsulinemia, hyperlipoidemia, atherosclerosis, hyperuricemia, the caused metabolism syndrome related symptoms containing uarthritis, and the like, regression neurosis containing Alzheimer's disease, Parkinson's disease, and the like, and similar symptoms. More concretely, the active ingredient of the microbiological preparation is a nonpathogenic germ for expressing active phenylalanine deaminase and/or phenylalnine ammonialyase, and the starting bacterial strain of the nonpathogenic germ is a natural bacterium or a genetic engineering bacterium.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of a microbial preparation in the prevention or treatment of diabetes, especially type 2 diabetes and related diseases. The related diseases include obesity, insulin resistance, hyperinsulinemia, hyperlipidemia, atherosclerosis, hyperuricemia and gout caused by hyperuricemia and other metabolic syndrome (metabolic syndrome, MS) related diseases and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. More specifically, the active ingredient of the microbial preparation is a non-pathogenic bacterium ( nonpathogenic microorganisms), the starting strain of the non-pathogenic bacteria is natural bacteria or genetically engineered bacteria. Background of the invention [0002] With the improvement of people's material living standards and changes in dietary structure, the incidence of diabetes and its related diseases, which is commonly known as "the diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A23L1/29A61P3/10A61P25/28A61P3/06A61P9/10A61P19/06A61P25/16A23L33/00A61K35/742
Inventor 萧湘
Owner 萧湘
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap